Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Can AI Improve Diabetic Retinopathy and Macular Degeneration Screening?
Tech & Innovation Can AI Improve Diabetic Retinopathy and Macular Degeneration Screening?

Medical advancements are progressing rapidly, and one of the most promising areas is artificial intelligence (AI) in diagnostic imaging. AI technology has the potential to revolutionize healthcare by enhancing the accuracy and efficiency of diagnoses. Acer Medical recently introduced two

Can AI Chatbots Like Therabot Revolutionize Mental Health Treatment?
Tech & Innovation Can AI Chatbots Like Therabot Revolutionize Mental Health Treatment?

In an age where artificial intelligence continues to pervade every aspect of daily life, the idea of AI chatbots stepping into the realm of psychotherapy is no longer a far-fetched concept. Imagine reaching a point where a simple conversation with a machine could lessen the burden of your anxieties

Is Merck's $2B Deal with Hengrui a Game-Changer for Cardiometabolic Drugs?
Research & Development Is Merck's $2B Deal with Hengrui a Game-Changer for Cardiometabolic Drugs?

The pharmaceutical landscape is rapidly evolving, and at the forefront of these advancements is Merck & Co.'s groundbreaking licensing agreement with Jiangsu Hengrui Pharmaceuticals, focusing on the innovative Lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This monumental $2 billion deal puts

How Can We Improve Access and Reimbursement for Precision Medicine?
Tech & Innovation How Can We Improve Access and Reimbursement for Precision Medicine?

Precision medicine offers significant promise in enabling targeted therapies for complex illnesses, making treatment more effective and patient-centered. However, the process of facilitating access and reimbursement for these therapies presents unique challenges. Unlike the more predictable path of

New National Health Rules Enhance Privacy for Medicare and PBS Data
Management & Regulatory New National Health Rules Enhance Privacy for Medicare and PBS Data

The introduction of the National Health (Privacy) Rules 2025 marks a significant shift in the privacy settings governing the handling of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) claims information by Australian Government agencies. Taking effect on April 1, 2025,

Advancements of AI Revolutionize Diagnostics and Treatment in Healthcare
Tech & Innovation Advancements of AI Revolutionize Diagnostics and Treatment in Healthcare

Artificial intelligence (AI) and machine learning (ML) represent transformative forces in modern healthcare that are unlocking unprecedented opportunities to improve diagnostic accuracy and optimize treatment plans. By integrating these sophisticated technologies into clinical practice, the

Should We Alter an Unborn Child's Sexual Orientation with Genetic Engineering?
Biotech & Bioprocessing Should We Alter an Unborn Child's Sexual Orientation with Genetic Engineering?

The notion of genetically engineering an unborn child's sexual orientation has stirred debates among ethicists, scientists, and religious groups. This discourse stems from the suggestion that, with advancements in scientific knowledge, it might be possible to determine an unborn child's

How Is Google Using AI to Revolutionize Global Health Outcomes?
Tech & Innovation How Is Google Using AI to Revolutionize Global Health Outcomes?

Google has long been at the forefront of technological innovation, and its efforts in the health sector are no exception. By leveraging advanced artificial intelligence (AI) capabilities, the tech giant aims to enhance global health outcomes through improved accessibility to quality health

GRObio Faces IP Conflicts and Investor Uncertainty Amidst Restructuring
Biotech & Bioprocessing GRObio Faces IP Conflicts and Investor Uncertainty Amidst Restructuring

GRObio, a spinout from the George Church Lab at Harvard University, has encountered significant hurdles lately. Founded in 2016, GRObio focuses on developing therapeutic proteins built on nonstandard amino acids (NSAAs). Despite its pioneering approach, the company is undergoing a period of

How Will the Genomic Data Protection Act Impact Consumers?
Management & Regulatory How Will the Genomic Data Protection Act Impact Consumers?

Ivan Kairatov is a Biopharma expert with extensive knowledge in technology and innovation within the industry and considerable experience in research and development. Today, we discuss the newly introduced Genomic Data Protection Act (GDPA) and its implications. Can you explain the main purpose of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later